Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses

Jared M Whitson, Catherine R. Harris, Maxwell V. Meng

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Study Type - Prognosis (cohort) Level of Evidence 2a What's known on the subject? and What does the study add? Case series of patients undergoing various forms of ablation show that it is technically feasible and possible for ablation to achieve short- and intermediate-term cancer-specific survival rates similar to those of controls undergoing partial nephrectomy. This is the first well-powered study with a controlled design to compare effectiveness between partial nephrectomy and ablation. OBJECTIVE To determine, in a population-based cohort, if disease-specific survival (DSS) was equivalent in patients undergoing ablation vs nephron-sparing surgery (NSS) for clinical stage T1a renal cell carcinoma (RCC). PATIENTS AND METHODS A retrospective cohort study was performed using patients from the Surveillance, Epidemiology and End Results cancer registry with RCC < 4 cm and no evidence of distant metastases, who underwent ablation or NSS. Kaplan-Meier and Cox regression analyses were performed to determine if treatment type was independently associated with DSS. RESULTS Between 1998 and 2007, a total of 8818 incident cases of RCC were treated with either NSS (7704) or ablation (1114). The median (interquartile range) follow-up was 2.8 (1.2-4.7) years in the NSS group and 1.6 (0.7-2.9) years in the ablation group, although 10% of each cohort were followed up beyond 5 years. After multivariable adjustment, ablation was associated with a twofold greater risk of kidney cancer death than NSS (hazard ratio 1.9, 95% confidence interval 1.1-3.3, P= 0.02). Age, gender, marital status and tumour size were also significantly associated with outcome. The predicted probability of DSS at 5 years was 98.3% with NSS and 96.6% with ablation. CONCLUSION After controlling for age, gender, marital status and tumour size, the typical patient presenting with clinical stage T1a RCC, who undergoes ablation rather than NSS, has a twofold increase in the risk of kidney cancer death; however, at 5 years the absolute difference is small, and may only be realized by patients with long life expectancies.

Original languageEnglish (US)
Pages (from-to)1438-1443
Number of pages6
JournalBJU International
Volume110
Issue number10
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Nephrons
Kidney
Renal Cell Carcinoma
Population
Kidney Neoplasms
Marital Status
Nephrectomy
Survival
Neoplasms
Social Adjustment
Life Expectancy
Registries
Epidemiology
Cohort Studies
Survival Rate
Retrospective Studies
Regression Analysis
Confidence Intervals
Neoplasm Metastasis

Keywords

  • ablation techniques
  • comparative effectiveness research
  • partial nephrectomy
  • renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses. / Whitson, Jared M; Harris, Catherine R.; Meng, Maxwell V.

In: BJU International, Vol. 110, No. 10, 11.2012, p. 1438-1443.

Research output: Contribution to journalArticle

Whitson, Jared M ; Harris, Catherine R. ; Meng, Maxwell V. / Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses. In: BJU International. 2012 ; Vol. 110, No. 10. pp. 1438-1443.
@article{b46529870b3f49d09115872ec3cb279f,
title = "Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses",
abstract = "Study Type - Prognosis (cohort) Level of Evidence 2a What's known on the subject? and What does the study add? Case series of patients undergoing various forms of ablation show that it is technically feasible and possible for ablation to achieve short- and intermediate-term cancer-specific survival rates similar to those of controls undergoing partial nephrectomy. This is the first well-powered study with a controlled design to compare effectiveness between partial nephrectomy and ablation. OBJECTIVE To determine, in a population-based cohort, if disease-specific survival (DSS) was equivalent in patients undergoing ablation vs nephron-sparing surgery (NSS) for clinical stage T1a renal cell carcinoma (RCC). PATIENTS AND METHODS A retrospective cohort study was performed using patients from the Surveillance, Epidemiology and End Results cancer registry with RCC < 4 cm and no evidence of distant metastases, who underwent ablation or NSS. Kaplan-Meier and Cox regression analyses were performed to determine if treatment type was independently associated with DSS. RESULTS Between 1998 and 2007, a total of 8818 incident cases of RCC were treated with either NSS (7704) or ablation (1114). The median (interquartile range) follow-up was 2.8 (1.2-4.7) years in the NSS group and 1.6 (0.7-2.9) years in the ablation group, although 10{\%} of each cohort were followed up beyond 5 years. After multivariable adjustment, ablation was associated with a twofold greater risk of kidney cancer death than NSS (hazard ratio 1.9, 95{\%} confidence interval 1.1-3.3, P= 0.02). Age, gender, marital status and tumour size were also significantly associated with outcome. The predicted probability of DSS at 5 years was 98.3{\%} with NSS and 96.6{\%} with ablation. CONCLUSION After controlling for age, gender, marital status and tumour size, the typical patient presenting with clinical stage T1a RCC, who undergoes ablation rather than NSS, has a twofold increase in the risk of kidney cancer death; however, at 5 years the absolute difference is small, and may only be realized by patients with long life expectancies.",
keywords = "ablation techniques, comparative effectiveness research, partial nephrectomy, renal cell carcinoma",
author = "Whitson, {Jared M} and Harris, {Catherine R.} and Meng, {Maxwell V.}",
year = "2012",
month = "11",
doi = "10.1111/j.1464-410X.2012.11113.x",
language = "English (US)",
volume = "110",
pages = "1438--1443",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses

AU - Whitson, Jared M

AU - Harris, Catherine R.

AU - Meng, Maxwell V.

PY - 2012/11

Y1 - 2012/11

N2 - Study Type - Prognosis (cohort) Level of Evidence 2a What's known on the subject? and What does the study add? Case series of patients undergoing various forms of ablation show that it is technically feasible and possible for ablation to achieve short- and intermediate-term cancer-specific survival rates similar to those of controls undergoing partial nephrectomy. This is the first well-powered study with a controlled design to compare effectiveness between partial nephrectomy and ablation. OBJECTIVE To determine, in a population-based cohort, if disease-specific survival (DSS) was equivalent in patients undergoing ablation vs nephron-sparing surgery (NSS) for clinical stage T1a renal cell carcinoma (RCC). PATIENTS AND METHODS A retrospective cohort study was performed using patients from the Surveillance, Epidemiology and End Results cancer registry with RCC < 4 cm and no evidence of distant metastases, who underwent ablation or NSS. Kaplan-Meier and Cox regression analyses were performed to determine if treatment type was independently associated with DSS. RESULTS Between 1998 and 2007, a total of 8818 incident cases of RCC were treated with either NSS (7704) or ablation (1114). The median (interquartile range) follow-up was 2.8 (1.2-4.7) years in the NSS group and 1.6 (0.7-2.9) years in the ablation group, although 10% of each cohort were followed up beyond 5 years. After multivariable adjustment, ablation was associated with a twofold greater risk of kidney cancer death than NSS (hazard ratio 1.9, 95% confidence interval 1.1-3.3, P= 0.02). Age, gender, marital status and tumour size were also significantly associated with outcome. The predicted probability of DSS at 5 years was 98.3% with NSS and 96.6% with ablation. CONCLUSION After controlling for age, gender, marital status and tumour size, the typical patient presenting with clinical stage T1a RCC, who undergoes ablation rather than NSS, has a twofold increase in the risk of kidney cancer death; however, at 5 years the absolute difference is small, and may only be realized by patients with long life expectancies.

AB - Study Type - Prognosis (cohort) Level of Evidence 2a What's known on the subject? and What does the study add? Case series of patients undergoing various forms of ablation show that it is technically feasible and possible for ablation to achieve short- and intermediate-term cancer-specific survival rates similar to those of controls undergoing partial nephrectomy. This is the first well-powered study with a controlled design to compare effectiveness between partial nephrectomy and ablation. OBJECTIVE To determine, in a population-based cohort, if disease-specific survival (DSS) was equivalent in patients undergoing ablation vs nephron-sparing surgery (NSS) for clinical stage T1a renal cell carcinoma (RCC). PATIENTS AND METHODS A retrospective cohort study was performed using patients from the Surveillance, Epidemiology and End Results cancer registry with RCC < 4 cm and no evidence of distant metastases, who underwent ablation or NSS. Kaplan-Meier and Cox regression analyses were performed to determine if treatment type was independently associated with DSS. RESULTS Between 1998 and 2007, a total of 8818 incident cases of RCC were treated with either NSS (7704) or ablation (1114). The median (interquartile range) follow-up was 2.8 (1.2-4.7) years in the NSS group and 1.6 (0.7-2.9) years in the ablation group, although 10% of each cohort were followed up beyond 5 years. After multivariable adjustment, ablation was associated with a twofold greater risk of kidney cancer death than NSS (hazard ratio 1.9, 95% confidence interval 1.1-3.3, P= 0.02). Age, gender, marital status and tumour size were also significantly associated with outcome. The predicted probability of DSS at 5 years was 98.3% with NSS and 96.6% with ablation. CONCLUSION After controlling for age, gender, marital status and tumour size, the typical patient presenting with clinical stage T1a RCC, who undergoes ablation rather than NSS, has a twofold increase in the risk of kidney cancer death; however, at 5 years the absolute difference is small, and may only be realized by patients with long life expectancies.

KW - ablation techniques

KW - comparative effectiveness research

KW - partial nephrectomy

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84868193585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868193585&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11113.x

DO - 10.1111/j.1464-410X.2012.11113.x

M3 - Article

VL - 110

SP - 1438

EP - 1443

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 10

ER -